Giselle Saulnier-Sholler
Beat Childhood Cancer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Giselle Saulnier-Sholler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:02 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06465199 · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center · recruiting · Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma
- Ph2NCT02395666 · Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in RemissionGiselle Sholler · completed · Neuroblastoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:02 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.PLoS One · 2015125 citationsRCR 3.7
- Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.J Clin Oncol · 202460 citationsRCR 7.9
- A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.Int J Cancer · 202053 citationsRCR 2.6
- A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.J Pediatr Hematol Oncol · 201140 citationsRCR 1.2
- A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.Clin Cancer Res · 202216 citationsRCR 1.2
- A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.Int J Cancer · 20239 citationsRCR 0.9